Research library
The research library
Every primary source behind a claim on this site, tier-graded for provenance and tagged for the strength of the evidence it carries.
- Sources indexed
- 221
- Peptides covered
- 44
- Tier 1 share
- 100%
- Matching filter
- 3
F·Filter
Reset allT1·Peer-primary literature
Randomized trials, peer-reviewed primary studies, and meta-analyses — the load-bearing layer of the corpus.
3 sources
- 2026Meta-analysismoderate
Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review
Batsis JA, Gavras A, Gross DC, +3 · Annals of Internal Medicine
Annals of Internal Medicine systematic review of 36 randomised controlled trials of liraglutide, semaglutide, tirzepatide, and dulaglutide in adults with obesity, evaluating fat mass, fat-free mass, lean soft tissue, and visceral adiposity outcomes against prespecified benchmarks — the most rigorous synthesis to date of the lean-mass concern that has dominated public discourse about incretin therapy.
- 2026Meta-analysismoderaten=1,593,554
Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis
Dhivagaran T, Butt F, Arunasalam L, +3 · Neurology
Across 1,593,554 patients in a Neurology-published meta-analysis (682,456 semaglutide users vs 911,098 non-GLP-1RA users), semaglutide use was associated with a 2.5-fold increased risk of nonarteritic anterior ischemic optic neuropathy (RR 2.52; 95% CrI 1.56–4.72), with the strongest signal in patients with diabetes (RR 2.41; 95% CrI 1.57–4.10) — the strongest meta-analytic confirmation to date that the NAION safety signal is real.
- 2010Meta-analysisstrongn=806
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Falutz J, Mamputu JC, Potvin D, +6 · Journal of Clinical Endocrinology & Metabolism
Pooled across two phase 3 trials in 806 ART-treated HIV patients with abdominal fat accumulation, tesamorelin reduced visceral adipose tissue and maintained the reduction for 52 weeks while preserving subcutaneous fat — the extended-evidence companion to the 2007 NEJM pivotal.